CES1 rs121912777: What Your Genotype Means
The genetic variant rs121912777 is a well-studied missense mutation within the CES1 gene, frequently referred to in medical literature as G143E. This variation leads to significantly impaired carboxylesterase 1 enzyme activity, altering how the liver processes certain medications, ester-containing compounds, and lipids. Depending on whether a drug is cleared or activated by this enzyme, carriers may experience altered therapeutic response or elevated medication concentrations.
What each genotype means
Typical enzyme activity
This is the most common genotype, representing the reference sequence for the CES1 gene. Individuals with this genotype typically exhibit standard carboxylesterase 1 enzymatic activity for processing endogenous lipids and therapeutic medications. No specific adjustments to medication metabolism are associated with this genotype.
This is the most common genotype observed across all global populations.
Reduced enzyme activity
This genotype indicates you carry one copy of the variant allele, which is associated with reduced carboxylesterase 1 enzymatic activity. This may alter how your body processes certain medications that rely on CES1 for bioactivation or metabolism. Please discuss your medication profile and potential dosing considerations with your clinician or pharmacist.
Carried by approximately 3% to 4% of people of European ancestry, based on a minor allele frequency of roughly 0.015 to 0.02.
Significantly reduced enzyme activity
This genotype indicates you carry two copies of the variant allele, which is linked to significantly reduced carboxylesterase 1 enzymatic activity. This reduction can impact the processing of specific drugs, potentially altering their therapeutic effectiveness or safety profile. It is important to discuss this genetic finding with your healthcare provider or pharmacist before starting or adjusting medications metabolized by this enzyme.
This genotype is rare, occurring in approximately 1 in 2,500 to 4,500 individuals of European ancestry, and is even less common in Asian populations.
What is rs121912777?
The single nucleotide polymorphism rs121912777 is located within exon 4 of the CES1 gene on human chromosome 16. At the molecular level, this variation represents a missense mutation that substitutes a glycine residue with glutamic acid at codon 143 of the protein, which is designated as p.Gly143Glu or simply G143E. Because glycine is replaced by an acidic amino acid near the catalytic pocket of the enzyme, the structural change severely compromises normal catalytic performance. According to records curated in ClinVar and OMIM, rs121912777 is classified under altered drug metabolism due to its functional disruption of ester hydrolysis. While typically cataloged as a single-base substitution, its clinical relevance stems from this direct, measurable loss of hydrolase function in liver tissues.
The Role of the CES1 Gene
The CES1 gene provides instructions for producing liver carboxylesterase 1, a predominant serine esterase and hydrolase expressed primarily in human hepatocytes and monocytes. Carboxylesterase 1 plays an essential dual role in human physiology: it metabolizes endogenous lipids such as cholesteryl esters and fatty acid esters, and it governs the biotransformation of a broad range of exogenous drugs. For many pharmaceuticals, CES1 acts as a primary clearance pathway by deactivating active ester compounds into inactive carboxylic acids. For other therapies, notably ester prodrugs, the enzyme is required to cleave specific chemical bonds to convert the inactive precursor into its therapeutically active metabolite. Consequently, variations that compromise CES1 enzyme output directly change hepatic clearance rates and systemic bioavailability.
Clinical and Pharmacogenetic Evidence
Functional pharmacogenetic studies consistently associate rs121912777 with marked shifts in substrate processing, though overall evidence strength is classified as limited to emerging due to small clinical cohort sizes. In foundational research, individuals carrying the G143E substitution demonstrated substantially reduced deactivation of methylphenidate, leading to elevated plasma drug concentrations and enhanced hemodynamic responses. Conversely, because the antiplatelet agent clopidogrel is partly hydrolyzed into an inactive form by CES1, decreased enzyme function shunts more drug toward active metabolite formation, correlating with stronger platelet inhibition in carrier studies. In vitro hepatic assays also show impaired activation of prodrugs such as dabigatran etexilate and sacubitril. While these mechanistic links are biologically robust, standard dosing algorithms across professional guidelines remain under active investigation.
Population Frequency and Ancestral Distribution
The minor allele associated with rs121912777 is relatively uncommon globally. Population genetic repositories and pharmacogenetic literature indicate that the minor allele frequency ranges between approximately 1.5% and 2.0% in populations of European ancestry. By contrast, the variant is substantially rarer or nearly absent in East Asian, South Asian, and African reference cohorts. Because the allele is uncommon, homozygous carriers are exceptionally rare in general populations, with the vast majority of individuals carrying either the standard functional genotype or a single altered allele as heterozygotes. Ongoing sequencing efforts continue to refine these frequencies across underrepresented populations.
Practical Implications and Medical Care
Discovering an altered genotype at rs121912777 provides valuable informational insight into individual metabolic tendencies, but it is not a direct disease diagnosis. Having this variant does not cause an organic illness on its own, nor does it guarantee an adverse drug reaction or therapeutic failure. Direct-to-consumer genetic profiles cannot replace clinical-grade diagnostic tests, and genotype findings should never prompt independent changes to prescribed treatment regimens. If an individual carries the G143E variant and is currently taking or considering medications metabolized by carboxylesterase 1—such as methylphenidate, clopidogrel, or dabigatran—they should discuss their personal profile with a qualified physician or clinical pharmacologist before making any dosing adjustments.
How common is this variant?
The minor allele frequency for rs121912777 is approximately 0.015 to 0.02 (1.5% to 2.0%) in individuals of European ancestry, while it is exceedingly rare or virtually absent in East Asian and African populations.
Frequently asked questions
What is the primary effect of the CES1 rs121912777 variant?
The variant causes a missense mutation known as G143E that alters the shape of the carboxylesterase 1 enzyme. This alteration significantly lowers the liver's ability to break down or activate specific medications and ester compounds.
Does having rs121912777 mean I have a disease?
No, carrying rs121912777 is not a disease in itself. It is a pharmacogenetic factor that affects how your liver metabolizes certain medications and lipid compounds.
Which medications are influenced by carboxylesterase 1?
Carboxylesterase 1 is involved in processing several common therapies, including methylphenidate, clopidogrel, dabigatran etexilate, and sacubitril. Depending on whether the drug is activated or deactivated by the enzyme, altered function can lead to increased active drug levels or decreased prodrug activation.
Should I change my medication dose if I carry this variant?
No, you should never alter your medication dosage or stop treatment based on genetic test results alone. If you have questions about your genotype and your current prescriptions, consult your doctor or clinical pharmacist.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121912777?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29